Clinical trial
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With…
NCT00055874 · Heidelberg University, Other · Completed
Key facts
| NCT number | NCT00055874 |
|---|---|
| Title | Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia |
| Official title | Treatment Optimization Trial in Chronic Myeloid Leukemia (CML) - Randomized Controlled Comparison of Imatinib vs. Imatinib/Interferon-alpha vs. Imatinib/Low-Dose AraC vs. Interferon-alpha Standard Therapy and Determination of the Role of Allografting in Newly Diagnosed Chronic Phase |
| Lead sponsor | Heidelberg University, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug, Procedure |
| Interventions | recombinant interferon alfa, cytarabine, hydroxyurea, imatinib mesylate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation |
| Enrollment | 1,551 |
| Start date | Jun 1, 2002 |
| Primary completion | Mar 31, 2012 |
| Completion | Mar 31, 2017 |
| First posted | Mar 7, 2003 |
| Last update posted | May 3, 2018 |
| Countries | Germany, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: